AIDS drug 3TC
Executive Summary
Canadian drug R&D firm IAF BioChem International announces that Phase I/II studies of the compound will begin in the U.S. in August. 3TC is being developed by Glaxo under an agreement with IAF.
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PS019508
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
PS019508
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.